The alcohol use disorder treatment market is estimated to grow by US$6.750 billion in 2018. The growing demand for the alcohol use disorder treatment is mainly attributed to the prevalence of this disease worldwide, with the high prevalence reported in Eastern European countries, parts of South East Asia and selected countries in Americas. According to the estimates by the Institute of Medicine, in 1996 the prevalence of Fetal Alcohol Syndrome (FAS) in the United States was between 0.5 and 3.0 cases per 1,000. As per the recent reports from the specific U.S. sites, the prevalence of FAS was found to be 2 to 7 cases per 1,000, and the prevalence of Fetal Alcohol Spectrum Disorders (FASD) was estimated to be as high as 20 to 50 cases per 1,000 (Source: National Institutes of Health). Furthermore, the rising number of deaths occurring due to alcohol-related liver disease is driving the market growth during the forecast period.
Major industry players profiled as part of the report are Teva Pharmaceuticals USA, Inc., Adial Pharmaceuticals, Alkermes, ADDEX THERAPEUTICS, Kinnov Therapeutics, OPIANT PHARMACEUTICALS, INC, Ethypharm, and MONTISERA LTD.
The alcohol use disorder treatment market has been analyzed through following segments:
Alcoholism (Alcohol dependence)
Middle East and Africa